Royal Bank of Canada
AKTX

Royal Bank of Canada’s Akari Therapeutics AKTX Stock Holding History

Royal Bank of Canada’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3
Closed – – 6989
2025
Q1 		$0 Buy
+3
New +$139 ﹤0.01% 6771
2017
Q1 		– Sell
-1
Closed -$4K – 6582
2016
Q4 		$4K Buy
+1
New +$6.46K ﹤0.01% 6340

Other funds holding AKTX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
OFW
Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Accent Capital Management Centerville, Ohio $206M AUM 29.56% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

Royal Bank of Canada's AKTX Position: Q2 2025 in Review

Royal Bank of Canada sold out of Akari Therapeutics (AKTX) in Q2 2025, closing a stake of 3 shares.

Royal Bank of Canada first reported a position in AKTX in Q4 2016 and held it in 2 quarters. The position peaked at $4K in Q4 2016. 13 funds tracked by Wall St. Rank hold AKTX as of Q2 2025.

  • Royal Bank of Canada reported no remaining Akari Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 3 Akari Therapeutics shares in Q2 2025.
  • Royal Bank of Canada first reported a position in Akari Therapeutics in Q4 2016 and held it in 2 quarters.
  • Royal Bank of Canada's Akari Therapeutics position peaked at $4K in Q4 2016.
  • 13 funds tracked by Wall St. Rank held Akari Therapeutics as of Q2 2025.

Based on Royal Bank of Canada's 13F filing for Q2 2025, filed 14 Aug 2025.